The Consortium for Clinical Research and Innovation, Singapore (CRIS) strengthens synergies and develops strategies for national clinical research and translation programmes that are under the stewardship of the Ministry of Health. It is a subsidiary of the Ministry of Health Holdings (MOHH).
At CRIS, we develop your career in tandem with your aspirations.
We are looking for great people who are passionate about advancing clinical research and innovation. From translational funding and strategic guidance, to scientific and operational study support, there is a role for everyone dedicated to impact change.
Join us and be part of our synergy.
About Our Programmes
SCRI
The Singapore Clinical Research Institute (SCRI) was established in 2008 as the national academic clinical research organisation to enhance the standards of clinical research in Singapore. In 2021, it was appointed as the national coordinating body to implement the national clinical trial strategy and enhance clinical trial ecosystem.
Precision Health Research, Singapore (PRECISE) was established in 2020 as the central entity to coordinate a whole-of- government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy.
The National Health Innovation Centre Singapore (NHIC) was established in 2014 as a nationally appointed Innovation and Enterprise Office that works with Public Healthcare Institutions across Singapore to identify, develop and commercialise promising clinical innovations to benefit patients and improve healthcare delivery.
The Singapore Translational Cancer Consortium (STCC) was established in 2020 as a nationally coordinated consortium to synergise cancer research capabilities in Singapore, bringing together unmatched basic, clinical and translational talent to create globally significant peaks of excellence in selected Asian cancers.
The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established in 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. It facilitates the discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine.
The Cardiovascular Disease National Collaborative Enterprise (CADENCE) was established in 2023 as a national clinical translational programme aimed at synergising cardiovascular research and technology capabilities across Singapore.
Please review the Data Protection Notice for Job Applicants before continuing with your job application. Your decision to proceed implies your acceptance to the policy.
